10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-ERK1 (C-terminal region) Antibody

Catalog # AN1783

Product Information

Application	WB, IHC, ICC
Primary Accession	P28482
Host	Mouse
Clonality	Mouse Monoclonal
Isotype	IgG1
Clone Names	M233
Calculated MW	41390

Additional Information

Gene ID	5594
Other Names	ERK, p42, p44, MAPK
Target/Specificity	Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs such as cell proliferation, differentiation, motility, and death. The ERK1/2 (p44/42) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines. Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK), a MAP kinase kinase (MAPKK), and a MAP kinase (MAPK). Multiple ERK1/2 MAPKKKs have been identified, including members of the Raf family as well as Mos and Tpl2/Cot. MEK1 and MEK2 are the primary MAPKKs in this pathway. MEK1 and MEK2 activate ERK1 and ERK2 through phosphorylation of activation loop residues Thr-202/Tyr-204 and Thr-185/Tyr-187, respectively. ERK1/2 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases. Several downstream targets of ERK1/2 have been identified, including p90RSK and the transcription factor Elk-1.
Dilution	WB~~1:1000 IHC~~1:100~500 ICC~~N/A
Storage	Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	Anti-ERK1 (C-terminal region) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.
Shipping	Blue Ice

Background

Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs such as cell proliferation, differentiation, motility, and death. The ERK1/2

(p44/42) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines. Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK), a MAP kinase kinase (MAPKK), and a MAP kinase (MAPK). Multiple ERK1/2 MAPKKKs have been identified, including members of the Raf family as well as Mos and Tpl2/Cot. MEK1 and MEK2 are the primary MAPKKs in this pathway. MEK1 and MEK2 activate ERK1 and ERK2 through phosphorylation of activation loop residues Thr-202/Tyr-204 and Thr-185/Tyr-187, respectively. ERK1/2 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases. Several downstream targets of ERK1/2 have been identified, including p90RSK and the transcription factor Elk-1.

Images



Western blot analysis of human A431 epithelial cells untreated (lanes 1 & 4) or treated with 100 nM calyculin A for 30 min. (lanes 2 & 5) or 100 ng/ml EGF for 60 min. (lanes 3 & 6). The blots were probed with anti-ERK1 (C-terminal region) (lanes 1, 2, & 3) or anti-ERK1/2 (Thr-202/Tyr-204) (lanes 4, 5, & 6).



Immunocytochemical labeling of ERK1 in paraformaldehyde-fixed and NP-40-permeabilized rabbit spleen fibroblasts. The cells were labeled with mouse monoclonal ERK1 (C-terminal region) and detected using appropriate secondary antibodies conjugated to Cy3.